|
| | | | |
|
 | | TEVA'S API DIVISION PLANT, PLANTEX IN NETANYA (ISRAEL) HAS RECEIVED ISO 14001 CERTIFICATION OF ENVIRONMENTAL MANAGEMENT SYSTEM | | | Teva Neuroscience, Inc. | | 03/10/2007 | | | The TAPI Plantex manufacturing site in Netanya, Israel has received ISO 14001 certification in accordance with the Israel Standards Institute. ISO 14001 defines standards for Environmental Management System and is the first of six criteria that define ISO 14000.
The standard for environmental management systems requires:
· Ongoing management commitment to improving environmental aspects of the operation in addition to compliance with legislation and regulation of pollution control.
· Establishment and execution of an environmental policy that includes setting and meeting specific measurable goals.
· Incorporate environmental considerations in production processes.
· Perform tests and ensure ongoing tracking of the environmental management system.
The environmental management system enables the organization to:
· Ensure achievement of its environmental goals
· Present its environmental actions to the community and authorities
Pursue commercial dealings with countries that require proof of compliance with an environmental policy. This trend is already apparent in some European countries and U.S. states.
Teva’s Active Pharmaceutical Ingredients (TAPI) Division is a stand alone business unit of Teva Pharmaceutical Industries Limited.
Founded in the 1930’s, TAPI has established itself over the years as a leading API supplier worldwide.
It offers a broad spectrum of active pharmaceutical ingredients for the worldwide pharmaceutical industry.
TAPI has 18 production sites worldwide, mainly located in Israel, Italy, Hungary, Mexico, Czech Republic Puerto Rico and India. They employ cutting edge technologies and state-of-the-art computerized systems in order to support high and consistent product quality, improved productivity and reliability. TAPI continuously invests in building and expanding the required production capacities. | |
|
| | | View similar articles: | | |
| | | |
|
 | People who viewed this article were also interested in |  | |  |
|
| Other articles from Teva Neuroscience, Inc. | | | |
|